OSE Immunotherapeutics acknowledges the decision of the Nantes Commercial Court

OSE Immunotherapeutics acknowledges the decision of the Nantes Commercial Court NANTES, France – September 23, 2025, 10:30 p.m. CET – OSE ...

OSE Immunotherapeutics publie sa position de trésorerie au 30 juin 2025

OSE Immunotherapeutics Reports its Cash Position as of June 30, 2025 Nantes, France, September 25, 2025, 6 p.m. CET - OSE Immunotherapeutics ...

Correction of a Material Error Relating to the Total Number of Voting Rights and Shares Comprising the Share Capital

Correction of a Material Error Relating to the Total Number of Voting Rights and Shares Comprising the Share ...
Investing.com South Africa

Ose Immunotherapeutics shares fall on AbbVie partnership delay

Investing.com -- Shares of Ose Immunotherapeutics dropped 4% in Paris trading Friday after the company announced delays in ...
Morningstar

OSE Immunotherapeutics provides an update on ongoing proceedings

Nantes, June 25th, 2025, 8:00 a.m. - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), announces that, following the hearing on June 24th, 2025, regarding the request to retract the June ...

OSE Immunotherapeutics, Inserm Transfert and Nantes University Announce Strategic Partnership to Accelerate Innovation in Immunotherapy

OSE Immunotherapeutics, Inserm Transfert and Nantes University Announce Strategic Partnership to Accelerate Innovation in ...
WDAF-TV

OSE Immunotherapeutics Reaffirms its Strategic Priorities and Publishes Shareholder Q&A to Restore Information Ahead of AGM

Nantes, August 29, 2025, 8:00 a.m. CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today published a comprehensive Questions and Answers document in advance of its Annual General ...
Morningstar

OSE Immunotherapeutics Board Urges Support for Value-Driving Strategy and Open-Minded Governance - Publication of Circular for Combined Annual General Meeting of September 30, 2025

Nantes, September 9, 2025, 8:30 p.m. CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) announces the release of preparatory documents for its Combined Annual General Meeting (AGM) ...
Business Wire

OSE Immunotherapeutics Announces New Public Grant to Support Innovation and Research Programs in the Field of RNA Therapeutics

NANTES, France--(BUSINESS WIRE)--Regulatory News: OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced that the Company has received €200,000 grant innovation funding from the ...
EurekAlert!

OSE Immunotherapeutics announces: positive phase 3 data from its cancer vaccine in lung cancer patients with resistance to previous immunotherapy published in Annals of Oncology

Nantes, France – September 11, 2023, 6:00pm CET – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced the peer-reviewed publication in Annals of Oncology* of the randomized ...
Business Wire

OSE Immunotherapeutics Receives First Notice of Allowance of a Patent for Use of Tedopi® to Treat Brain Metastasis

NANTES, France--(BUSINESS WIRE)--Regulatory News: OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE) (Paris:OSE), today announced that the Japanese Patent Office has issued the notice of ...